Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid TumorsZURICH, SWITZERLAND, May 05, 2025 (GLOBE NEWSWIRE) -- ...

The collaboration brings together OmniAb’s suite of transgenic antibody discovery solutions with Veraxa’s proprietary antibody drug conjugate (ADC) linker technology and conjugation expertise to ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today shared new preclinical data for ...

The CDC’s ACIP updated guidance on pneumococcal vaccination, recommending a single dose of PCV for all adults aged 50 years and older.

VERAXA Biotech AG ( VERAXA) has entered a co-discovery alliance with OmniAb, Inc. for the development of a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors.

Cidara Therapeutics shifted its focus from antifungal treatments to its proprietary Cloudbreak drug Fc conjugate platform.

Partnership Combines VERAXA's Proprietary ADC Technology with OmniAb's Antibody Discovery Technology for Novel Therapies Targeting Solid TumorsZURICH, SWITZERLAND, May 5, 2025 -- VERAXA Biotech AG(NAS ...

University of Edinburgh scientists have harnessed the power of AI in a new tool that promises to speed up analysis of data ...

Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how ...